SCHEMBL5055408

SCHEMBL5055408

C=NOCCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5058853 0.81
SCHEMBL20160138 0.74
SCHEMBL20237126 0.73
SCHEMBL31392761 0.69
SCHEMBL5055404 0.67
SCHEMBL18699362 0.67
Ethylenediamine SCHEMBL11023353 0.63
Ethylenediamine SCHEMBL9190307 0.63
SCHEMBL12239875 0.62
SCHEMBL3439517 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004083365-A9 COMPOUNDS AND THEIR USE FOR SPECIFIC AND SIMULTANEOUS INHIBITION OF GENES INVOLVED IN DISEASES AND RELATED DRUGS INST NAT SANTE RECH MED (FR) 2008-07-10 WO claimed
US-20080108581-A1 Compounds and Their Use for Specific and Simultaneous Inhibition of Genes Involved In Diseases and Related Drugs INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (I.N.S.E.R.M.) (FR) 2008-05-08 US claimed
JP-2006523646-A 2006-10-19 JP claimed
EP-1606405-A2 COMPOUNDS AND THEIR USE FOR SPECIFIC AND SIMULTANEOUS INHIBITION OF GENES INVOLVED IN DISEASES AND RELATED DRUGS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2005-12-21 EP claimed
WO-2004083365-A2 COMPOUNDS AND THEIR USE FOR SPECIFIC AND SIMULTANEOUS INHIBITION OF GENES INVOLVED IN DISEASES AND RELATED DRUGS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2004-09-30 WO claimed
CN-102869660-A Aminothiazolones as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV 2013-01-09 CN disclosed
CN-102834392-A Aminothiazolones as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV 2012-12-19 CN disclosed
CN-101679326-B Substituted phenoxy n-alkylated thiazoledinedione as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV 2012-12-12 CN disclosed
CN-102770429-A Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV 2012-11-07 CN disclosed
CN-101355876-B Composition suitable for ophthalmic administration COMBINATORX INC 2012-09-05 CN disclosed
CN-101679326-A Substituted phenoxy n-alkylated thiazoledinedione as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV 2010-03-24 CN disclosed
CN-101679322-A Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV 2010-03-24 CN disclosed
CN-101355876-A Methods, compositions and kits for treating medical conditions COMBINATORX INC (US) 2009-01-28 CN disclosed
CN-101102760-A Methods and agents for treating immunoinflammatory disorders COMBINATORX (US) 2008-01-09 CN disclosed
CN-100355714-C Arylpiperazines having 5-hydroxyl-typtamine activity LILLY CO ELI (US) 2007-12-19 CN disclosed
CN-1889956-A Methods and reagents for the treatment of immunoinflammatory disorders COMBINATORX INC (US) 2007-01-03 CN disclosed
CN-1761478-A Combination therapy for the treatment of immunoinflammatory disorders COMBINATORX INC (US) 2006-04-19 CN disclosed
CN-1743302-A Arylpiperazines having 5-hydroxyl-typtamine activity LILLY CO ELI (US) 2006-03-08 CN disclosed
CN-1227241-C Having 5-hydroxytryptamine 1AReceptor-active arylpiperazines LILLY CO ELI (US) 2005-11-16 CN disclosed
CN-1290258-A Aryl piperazine compounds with 5-hydroxytryptamine 1A receptor activity LILLY CO ELI (US) 2001-04-04 CN disclosed